XXXX : incidence and treatment of genitourinary sequelae.

@entity1 @entity548 @entity4917 @entity811 @entity790
PURPOSE: Prior reviews regarding genitourinary manifestations of @entity4917 used data acquired from diverse specialty specific articles to define the incidence and sequelae of its genitourinary manifestations. We believe that this resulted in erroneous conclusions regarding the urological complications of @entity4917 . MATERIALS AND METHODS: Data on genitourinary manifestations in @entity1 with @entity4917 treated at 1 institution from 1970 through 2005 were acquired. RESULTS: Of 218 @entity1 with @entity4917 30% (66 of 218) had genitourinary involvement, including 7% (15) with @entity790 , 7% (15) with visceral genitourinary involvement and 16% (36) with each type. Intermittent @entity548 from @entity790 developed in 65% of @entity1 (33 of 51). Conservative treatment with compression and/or cauterization was attempted in all 33 @entity1 and it was successful in 64% (21 of 33). Intractable @entity548 resulted in excision of the cutaneous @entity548 site in 36% of cases (12 of 33). A total of 39 hospitalizations for gross @entity811 occurred in 9% of the @entity1 (19 of 218). @entity811 developed from the bladder in 11 cases, the urethra in 4 and the kidney in 4. Conservative therapy resolved gross @entity811 in 21% of the @entity1 (4 of 19). Refractory @entity811 was successfully treated with cauterization in 37% of the @entity1 (7 of 19) and by angiographic embolization in 10% (2 of 19). Intractable gross @entity811 resulted in open surgical excision of the @entity548 site in 32% of the @entity1 (6 of 19). CONCLUSIONS: The incidence of genitourinary manifestations of @entity4917 is 30%, which is triple the previously reported incidence of 9%. Unlike prior reports stating that the @entity790 rarely caused problems, 52% of the @entity1 (34 of 66) with @entity4917 who had urological manifestations eventually required interventional therapy for genitourinary complications.
